Jaclyn Rudzinski, MD (@JLRudzinskiMD) header
Jaclyn Rudzinski, MD (@JLRudzinskiMD) profile picture

AP CP cytology boarded pathologist | BSWH hospital laboratory medical director | Posts are so I remember the lesson | #surgpath #cytopath

Joined November 2019
Photo by Jaclyn Rudzinski, MD (@JLRudzinskiMD)Photo by Jaclyn Rudzinski, MD (@JLRudzinskiMD)Photo by Jaclyn Rudzinski, MD (@JLRudzinskiMD)Photo by Jaclyn Rudzinski, MD (@JLRudzinskiMD)Photo by Jaclyn Rudzinski, MD (@JLRudzinskiMD)Photo by Jaclyn Rudzinski, MD (@JLRudzinskiMD)Photo by Jaclyn Rudzinski, MD (@JLRudzinskiMD)Photo by Jaclyn Rudzinski, MD (@JLRudzinskiMD)Photo by Jaclyn Rudzinski, MD (@JLRudzinskiMD)Photo by Jaclyn Rudzinski, MD (@JLRudzinskiMD)
Eosinophilic vacuolated tumor (EVT) of kidney. ​ Can occur sporadically or as part of tuberous sclerosis complex/TSC. Somatic or germline mutations in the TSC1, TSC2, or MTOR genes. #gupath #pathX
3
10
594
A review of the differential diagnosis for soft tissue neoplasms found in a routine "lipoma" specimen #pathX
78
Very subtle
nice example of subtle "microcystic" pattern prostatic adenocarcinoma (still 3+3; incidental here at time of cystectomy for uro ca) paired PIN4 #IHCpath shown pathologyoutlines.com/topic/…
163
Mesothelioma, a nice clinicopathologic correlation thread.
Replying to @HemeOncBuddy
1️⃣ Risk & epidemiology 👉 Asbestos in ~80%; latency 20-40 yr; crocidolite > amosite > chrysotile. 👉 Also erionite (Cappadocia), prior chest RT, germline BAP1. 👉 Smoking does NOT raise mesothelioma risk. 👉 Pleural ~80% (M:F 5:1); peritoneal ~20% (1:1).
1
1
2
380
Jaclyn Rudzinski, MD retweeted
One look at this intraoperative smear prep and you can diagnose this brain tumor. #pathology #neuropath #pathtwitter
12
25
1
108
4,999
E-cadherin breakdown in ILC (slide 2): 85% negative 15% positive and abnormal #breastpath
Outstanding debate with @fouad_boulos & @SchnittStuart moderated by @AnneAvincent on use of E-cadherin to diagnose lobular carcinoma at the International Invasive #Lobular Symposium 2026! Do you use morphology only or E-cadherin IHC to diagnose ILC? Poll 👇 #PathX #breastpath
311
LLMs are so good at quantitative (counting, measuring) Yes to quant. w/o a whole slide scanner For fun, try hey Googling, "Are the brown staining cells in the lymph node ITCs or micrometastasis? Black hash marks are 1 mm."
Can Ki-67 counting go digital—without a whole-slide scanner? 🔬💻 A new JCP study puts several digital approaches to the test for Ki-67 quantification in gastrointestinal well-differentiated neuroendocrine tumours (NETs). - 68 NETs were evaluated using manual counting vs digital image analysis - QuPath, ImageJ and ChatGPT-based colour segmentation showed strong agreement with manual Ki-67 counting - Even simple microscope camera-captured images performed comparably to whole-slide images - Grade changes were uncommon—and occurred mainly around the critical Ki-67 cut-off values - Some platforms performed better than others, highlighting the importance of validation before clinical use Why does this matter? Digital Ki-67 assessment may not have to depend on expensive whole-slide imaging infrastructure. Open-source tools + a microscope camera could make more reproducible quantification accessible to a much wider range of laboratories. 📖 Open access article linked here: bit.ly/4crJUdp #JCPJournal #DigitalPathology #Pathology #Ki67 #NeuroendocrineTumor #ArtificialIntelligence #QuPath #ImageAnalysis #openaccess
315
Jaclyn Rudzinski, MD retweeted
Here's to another great year on the Forty Acres! 🧡 Happy Birthday, UT 🎂
6
41
5
400
9,286
Pathology correlate, here is a mucinous borderline ovarian tumor. Size > 20 cm. ​Mucinous tumors of the ovary require extra tissue to be examined to exclude microinvasion, etc. We also rule out metastasis. ​In this case, neoplastic mucinous epithelium was low grade throughout.
Mucinous borderline ovarian tumor = Epithelial tumor of low malignant potential. Large tumor (blue) with mass effect against bladder (B). Multiple internal septations better seen on US (orange). Mucinous tumors tend to be Massive & Multilocular compared w/ serous tumors. #FOAMrad
2
4
541
Jaclyn Rudzinski, MD retweeted
This mammary myofibroblastoma arose in a man's breast (this lesion is more common in men than women). It co-expressed desmin and CD34; Rb protein loss would be anticipated! Good bread and butter!
1
18
1
45
2,405
Jaclyn Rudzinski, MD retweeted
A dramatic example of hepatic amyloidosis!
4
51
181
5,419
Jaclyn Rudzinski, MD retweeted
“Pseudo–signet ring cells in ascitic fluid: a deceptive look that can lead you straight to the wrong diagnosis.” Hydropic degeneration is known to occur in histiocytes and mesothelial cells. (Cytospin preps)
2
32
4
131
4,208
Jaclyn Rudzinski, MD retweeted
Dolly Parton’s niece, Hannah Dennison, was diagnosed with leukaemia at the age of 4, and underwent treatment at Monroe Carell Jr. Children’s Hospital at Vanderbilt. The family didn’t know whether Hannah would survive and she received treatment for nearly 4 years. Hannah did survive and made a full recovery. Dolly believed this showed that miracles do happen. She wrote the song “Chemo Hero” as a tribute to her niece and the medical team. She later returned to the same hospital to perform the song for sick children and surprised the hospital by donating $1 million to its paediatric cancer programme Rest in peace beautiful soul 💜
21
679
22
8,573
233,890
2nd grader wanted to bike to school today. We made it in plenty of time. It was a special boy mom moment, as many iterations went into this moment.
Quality assurance at home 🏡 We are not going off-roading RN. Look straight at the yellow line, fixed it.
1
2
291
Jaclyn Rudzinski, MD retweeted
Dr. Stephen Biebelhausen may have been doing the running, but Blake looks fully committed to the effort! Those legs were kicking straight to the finish line! Together, the father-daughter duo clocked a record-breaking 4:17 run @GuardianMile. 🙌
1
3
11
9,592
Jaclyn Rudzinski, MD retweeted
Dr. Stephen Biebelhausen may have been doing the running, but Blake looks fully committed to the effort! Those legs were kicking straight to the finish line! Together, the father-daughter duo clocked a record-breaking 4:17 run @GuardianMile.🙌
1
3
11
1,224
Jaclyn Rudzinski, MD retweeted
Friday Xposé 🤓 We’re all familiar with the difficulty in properly classifying fibroepithelial lesions of the breast. Distinguishing fibroadenoma (FA) from benign phyllodes tumor (PT) is what we struggle with most often, and that’s because most of us accept the idea of a pericanalicular growth pattern in PT. In other words, the large leaf-like fronds that gave the tumor its name need not be present to make the diagnosis. And fibroadenomas can have focal leaflike architecture as well, so go figure. I am personally convinced that, short of a molecular fingerprint proving a neoplastic stromal component, it is largely impossible to accurately diagnose lesions with overlapping morphology. Fortunately, benign PT and FA are essentially clinically identical and a misdiagnosis, which I believe to be quite common, does not lead to untoward patient outcomes. Things get a little trickier when we have to decide whether a PT is borderline or malignant. The latest iteration of the WHO blue book, by requiring all malignant features to be present before dishing out a malignant diagnosis, was clearly more concerned with interobserver agreement and likelihood of malignant behavior than capturing most cases that could act aggressively and labeling them as malignant. This stance has of course generated a few rebuttals, generally pointing out that PT can metastasize and be fatal even if not all the WHO criteria are present. The most recent publication to that effect is a multi-institutional one from the AJSP looking at a significant number of PTs diagnosed as malignant, their histologic characteristics, which of them metastasized, and which were fatal. As expected, a large proportion of the tumors that were clinically malignant did not fully satisfy the WHO requirements (see attached). Here's my relatively naive take on the matter. 1. ​First, a terminology revamp may be needed. Both conventional wisdom and patient perception expect that a borderline PT may be more of a locally aggressive affair, but should hardly be capable of distant metastasis. In reality, a borderline PT is a low-grade malignancy with unexpected behavior, a little like low-grade fibromyxoid sarcoma with metastasis rates in the single digits. Yet LGFMS is called a sarcoma. Low malignant potential is another term used for tumors that uncommonly metastasize, but have the capacity to do so. Is it justified to label someone with a low-grade malignancy given all the psychological and insurance-related concerns that would derive from this label? That's a philosophical question that is beyond the scope of this discussion. Personally, I think the problem with making the shift to a more accurate depiction of PTs is how morphologically diverse and heterogeneous they are and how difficult it is for us to predict behavior when the tumor is NOT histologically malignant. But calling them borderline may be misleading patients and clinicians alike. 2. It does seem like the WHO jumped the gun a little bit with their strict criteria for diagnosing a malignant PT. Let me put it this way. It is essentially unheard of in pathology to NOT call something malignant when it fulfills all histologic criteria of malignancy. In other words, if the stroma, as seen in the case that prompted this discussion, is cellular, highly pleomorphic, and mitotically active to the tune of 5 mitoses in a single high-power field including atypical forms, does this proliferation not have the potential to metastasize? I believe that it does, and at the very least, I believe we should assume that it does. Would stromal overgrowth and permeative growth increase the likelihood of malignant clinical behavior? Yes of course. It's all a question of odds. 3. Permeative growth should not have been included in the criteria for malignancy. Soft tissue sarcomas are notoriously well-circumscribed, but this has never stopped them from littering the lungs with nodules. Stromal overgrowth is a more appropriate measure of the independently expansile nature of the neoplastic stroma. Would you call something that looks like a high-grade sarcoma borderline and risk undertreatment just because it is well-circumscribed? I don't think you should. Going back to the index case, this PT was called borderline and excised a year ago with positive margins, the ugly areas were limited, and it was not re-excised. Now it's back, almost 5 cm strong, with a uniformly malignant-looking stroma and positive margins again. I will not take chances regardless of what the WHO recommends. I called it a malignant phyllodes tumor. @wusm_pathology @washupathedu #breastpath #PathX #PathTwitter #breastcancer
6
28
1
84
6,090
Peripheral blood smear, routine preparation Patient with recent travel outside the United States #pathX
Infectious disease diagnosis often requires taking a good travel history
1
2
504
This was a case of malaria. It's rainy season in Western Africa. Summer is also travel season for the United States. Not all patients get admitted. Some are discharged home from the emergency room with antimalarial medication.
54
Infectious disease diagnosis often requires taking a good travel history
“Endemic” means lots of people have an infection in a given geographic area. That affects what you see as a pathologist In India, as a pathology resident I saw TB and leprosy every day, leishmaniasis and malaria every week Where I live now, I see this #pathology #pulmpath
2
1
6
1,635